SecBot SecBot
Biotech Drug Report Generated Jul 6, 2026

EYLEA HD

REGN·REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and on the market (since August 2023)
Why 4/10
EYLEA HD is already FDA-approved and commercially marketed (Aug 2023 for wAMD/DME; Nov 2025 for RVO; Apr 2026 for extended dosing up to every 20 weeks). There is no pending binary PDUFA or pivotal readout for this drug in the next ~12 months. It is an important product within Regeneron's portfolio but is not the dominant value driver (Dupixent is larger), and the stock's next major catalysts are elsewhere (e.g., garetosmab PDUFA Aug 2026).
Actionable Insight NEUTRAL

EYLEA HD is a mature commercial asset, watch quarterly sales trends as a pulse check on how well Regeneron is defending share against Roche's Vabysmo and upcoming biosimilars (Samsung Bioepis Opuviz eligible Jan 2027). The real binary catalyst for REGN in the next 12 months is garetosmab's PDUFA in August 2026 for FOP. EYLEA HD's contribution is a gradual commercial story, not a binary event.

Price Chart

Loading chart...

Executive Summary

EYLEA HD (aflibercept 8 mg) is Regeneron's higher-dose follow-up to its blockbuster eye drug EYLEA (2 mg). Approved by the FDA in August 2023 for wet AMD and DME, and expanded to RVO (Nov 2025) and extended dosing up to every 20 weeks (Apr 2026), it's designed to fend off competition from Roche's fast-growing Vabysmo and upcoming biosimilars. In Q1 2026, EYLEA HD generated $468M in U.S. sales, up 52% YoY, but the total EYLEA franchise continues to shrink as original EYLEA declines under pressure. With EYLEA HD already fully approved and no pending binary regulatory catalyst, it's a commercial defense story, important but not the company's most impactful near-term catalyst.

How It Works

EYLEA HD is an anti-VEGF drug. It's a modified protein that acts like a sponge to soak up excess vascular endothelial growth factor (VEGF) in the eye. VEGF is a signaling protein that causes abnormal, leaky blood vessels to grow in the retina, the main culprit in wet AMD, diabetic eye disease, and retinal vein occlusion. By neutralizing VEGF, EYLEA HD stops the leakage and abnormal growth, preserving vision. EYLEA HD is the higher-dose (8 mg) version of the original EYLEA (2 mg), allowing patients to go longer between injections, up to every 16-20 weeks for some indications versus every 4-8 weeks with the original.

Trial Status

EYLEA HD was approved by the FDA in August 2023 for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) based on the Phase 3 PULSAR and PHOTON trials. In November 2025, the FDA approved it for macular edema following retinal vein occlusion (RVO) based on the Phase 3 QUASAR trial. In April 2026, the FDA approved extended dosing intervals up to every 20 weeks for wAMD and DME. A 3-year extension study of PULSAR published in February 2025 showed sustained durability. A separate sBLA for a pre-filled syringe manufacturing line received a Complete Response Letter in October 2025; a resubmission PDUFA passed in April 2026 without FDA action.

The Two-Sided Case

▲ Bull Case5
EYLEA HD's extended dosing interval (up to every 20 weeks) is a meaningful competitive advantage over both the original EYLEA and some competitors, fewer injections is a strong selling point for patients and physicians.
Q1 2026 U.S. net sales of $468M were up 52% YoY, showing rapid uptake as patients and doctors transition from the original EYLEA to the higher-dose formulation.
The total addressable market for anti-VEGF eye drugs is large and growing, analysts project Vabysmo and EYLEA HD combined could generate $13.2B by 2030.
Regeneron has a strong patent portfolio and has secured settlement agreements pushing biosimilar entry to at least January 2027 (Samsung Bioepis).
The drug benefits from Regeneron's established commercial infrastructure and long-standing relationships with retina specialists.
▼ Bear Case6
Roche's Vabysmo (faricimab) continues to gain market share rapidly, it grew to ~CHF 3.9B in 2024 and Q2 2025 sales of CHF 1.05B were up 19% YoY, directly pressuring the EYLEA franchise.
Total EYLEA franchise (original + HD) global sales fell 17% in 2025 to $7.9B from $9.5B in 2024, and combined U.S. sales were down 28% YoY in Q3 2025.
Biosimilar competition is coming: Samsung Bioepis can launch Opuviz (aflibercept biosimilar) in the U.S. from January 2027, and Amgen's high-dose 8 mg biosimilar (ABP 938) is in Phase 3 trials.
Ocular Therapeutix posted a Phase 3 win for its wet AMD drug that beat Eylea on key endpoints, signaling potential future competition from sustained-delivery platforms.
The pre-filled syringe sBLA received a CRL in Oct 2025 and the resubmission PDUFA in Apr 2026 passed without action, creating manufacturing/supply overhangs.
Analysts have been lowering REGN price targets (Citi downgraded to Neutral, Leerink to Market Perform, and multiple firms cut targets in May 2026) partly due to Eylea franchise erosion concerns.

Upcoming Catalysts

  • Quarterly EYLEA HD and total EYLEA franchise sales reports (next: Q2 2026 late July 2026), key to track whether HD growth is offsetting original EYLEA decline.
  • Samsung Bioepis Opuviz (aflibercept biosimilar) launch eligibility date: January 2027, potential step-change in competitive pressure.
  • Potential resubmission/update on pre-filled syringe (PFS) manufacturing sBLA for EYLEA HD.
  • Amgen's Phase 3 trial update for ABP 938 (8 mg aflibercept biosimilar).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report

Sources · 13

Hover a chip for the title
1 morningstar.com2 fiercepharma.com3 benzinga.com4 investor.regeneron.com5 fiercepharma.com6 biospace.com7 healio.com8 fiercepharma.com9 fiercepharma.com10 market-scope.com11 jdsupra.com12 pearceip.law13 sec.gov